The Latest Cardiac and Vascular News
DENVER and WASHINGTON, March 2, 2022 /PRNewswire/ — DispatchHealth, the nation’s first comprehensive in-home high acuity medical provider, today announced its collaboration with The American College of Cardiology (ACC), a nonprofit professional medical society, to enhance the lives of cardiovascular disease patients. The first of its kind, the collaboration between DispatchHealth and ACC is designed to […]
Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of aficamten, an investigational next-generation cardiac […]
SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28, 2022 it granted stock options to purchase an aggregate of 86,850 shares of common stock to eight new employees, whose employment commenced in February 2022, as a material inducement to […]
BRISBANE, Australia and EAGAN, Minn., March 02, 2022 (GLOBE NEWSWIRE) — Anteris Technologies Ltd (Anteris or the Company) Limited (ASX: AVR) announces the Company has entered a binding agreement to place 1,840,000 new Ordinary Shares (New Shares) raising USD 20 million ($A 28 million) to Perceptive Life Sciences Master Fund, […]
Business Associate Agreement and Clinical Trial Agreement with Additional Planned Studies and Commercial and Scientific Collaboration SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has signed a Business Associate Agreement (BAA) and Clinical […]
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the expansion of its Scientific Advisory Board (SAB) with four newly appointed cardiology and RNA drug development experts. Johann Bauersachs, MD; Perry Elliott, MD; Gerasimos Filippatos, MD, PhD; and Barry […]
Mr. Havis will Lead Commercialization from Europe to Asia YOKNEAM, Israel & MIAMI–(BUSINESS WIRE)–Rapid Medical, a leading developer of neurovascular devices, announces the promotion of Eitan Havis to President, International. Mr. Havis will oversee the commercial expansion of the company’s advanced neurovascular technologies to treat hemorrhagic and ischemic stroke patients in Europe, […]
REDWOOD CITY, CA / ACCESSWIRE / February 28, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians in the U.S. have successfully completed first cases with its new […]
John Farquhar Appointed CEO, John Stevens to Become Vice Chair, Board of Directors MOUNTAIN VIEW, Calif., March 01, 2022 (GLOBE NEWSWIRE) — HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced that John Farquhar has been appointed President and Chief Executive Officer, effective March 1, 2022. Mr. Farquhar has […]
MINNEAPOLIS, March 01, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the fourth quarter and full year ended December 31, 2021, which included the following highlights: Generated $1.6 million in total revenue for the fourth quarter 2021, 19.6% below the prior-year period and a 20% […]
